Recommendations for Initiating Systemic Therapy in Patients with Psoriasis

Area of Science:

• Dermatology
• Immunology
• Systemic Inflammatory Diseases

Background:

• Psoriasis is a chronic, systemic inflammatory condition frequently linked to comorbidities like cardiovascular disease, obesity, and diabetes.
• Many patients with moderate-to-severe psoriasis experience treatment dissatisfaction and impaired quality of life, often receiving only topical therapy.
• Topical monotherapy is frequently insufficient for managing moderate-to-severe psoriasis, highlighting a need for more effective treatment strategies.

Purpose of the Study:

• To provide a rationale for initiating systemic therapy in patients with moderate-to-severe psoriasis.
• To discuss barriers to systemic agent use and emphasize patient-centered assessment of disease severity.
• To identify practical strategies for selecting and safely initiating systemic treatments to optimize psoriasis management.

Main Methods:

• Review of current literature on psoriasis treatment guidelines and systemic therapies.
• Analysis of patient-reported outcomes and treatment satisfaction with various therapeutic approaches.
• Discussion of the benefits, risks, and monitoring requirements of different systemic agents, including oral and biologic options.

Main Results:

• Systemic therapies are more effective than topical monotherapy in reducing psoriasis symptoms and achieving treatment targets.
• A variety of systemic treatment options exist, including conventional and novel oral agents, as well as biologics, each with distinct profiles.
• Patient perspective is crucial in assessing disease severity and guiding treatment decisions.

Conclusions:

• Systemic therapy can significantly improve outcomes for patients with moderate-to-severe psoriasis who are inadequately managed with topical treatments.
• Careful consideration of individual patient factors, treatment benefits, safety risks, and monitoring is essential for optimizing systemic therapy selection and initiation.
• Addressing barriers and adopting patient-centered strategies can enhance the effective use of systemic agents in psoriasis management.